Physician profile
James E Splichal
NPI 1588619142
$21,886.58
in general payments reported to CMS, 2019-2025
91 companies · $3,306 in 2025
The $3,306 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,520 · 2020: $1,827 · 2021: $3,189 · 2022: $3,821 · 2023: $3,498 · 2024: $3,727 · 2025: $3,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,463 · Long Term Medical Supply Or Device Loan: $833 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,463.07 |
| Long Term Medical Supply Or Device Loan | $833.30 |
| Education | $233.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,839.82 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,770.98 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $1,047.26 | 2019-2025 | Darzalex, Erleada, Talvey |
| Celgene Corporation | $921.72 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $794.80 | 2019-2025 | |
| Seagen INC. | $760.75 | 2019-2023 | Adcetris, Tivdak, Tukysa |
| Glaxosmithkline, LLC. | $718.07 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Genentech USA, INC. | $649.98 | 2019-2025 | Polivy, Lunsumio, Venclexta |
| Incyte Corporation | $611.48 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $581.91 | 2019-2025 | Iclusig, Fruzaqla, Ninlaro |
| Bayer Healthcare Pharmaceuticals INC. | $571.45 | 2019-2025 | |
| Daiichi Sankyo INC. | $571.24 | 2019-2025 | Enhertu |
| Gilead Sciences, INC. | $546.14 | 2021-2025 | Trodelvy |
| Amgen INC. | $498.42 | 2019-2023 | Kyprolis, Vectibix, Xgeva |
| Astrazeneca Pharmaceuticals Lp | $481.46 | 2019-2025 | Lynparza, Calquence, Imfinzi |
Show all 88 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Splichal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.